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Abstract
Background: The aim of this study was to systematically assess the efficacy and safety of mineralocorticoid
receptor antagonists (MRAs) for patients with heart failure (HF) and diabetes mellitus (DM).
Methods: We conducted a comprehensive search for controlled studies that evaluated the efficacy and safety of
MRAs in patients with DM and HF. Medline, Embase and Cochrane databases were searched. Two reviewers
independently identified citations, extracted data and evaluated quality. Risk estimations were abstracted and
pooled where appropriate.
Results: Four observational studies were included. MRAs use was associated with reduced mortality compared with
controls (RR = 0.78; 95 % CI: 0.69–0.88; I 2 = 0 %; P < 0.001). Increased risk of developing hyperkalaemia was observed
in those patients taking MRAs (RR = 1.74; 95 % CI: 1.27–2.38; I 2 = 0 %; P = 0.0005).
Conclusions: The current cumulative evidence suggests that MRAs can improve clinical outcomes but increase the
risk of hyperkalaemia in patients with DM and HF.
Trial registration: PROSPERO CRD42015025690.
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Background
Diabetes mellitus (DM) and heart failure (HF) com-
monly coexist. About 40 % of hospitalized HF patients
have DM, and these figures are expected to grow with
the general aging of the population [1]. Results from
more than 100,000 patients in the Acute Decompensated
Heart Failure National Registry suggested that 44 % of
HF patients had DM [2]. Results from a health mainten-
ance organization show that about 12 of 10,000 patients
with DM had HF at baseline, and 3.3 % of the rest devel-
oped HF during each year of follow-up [3]. There is now
a large number of epidemiological and clinical data
supporting the strong association between HF and DM
[4]. Patients with HF can have insulin resistance, which
increases their risk of developing type 2 DM [5]. It was
shown in an Italian observational study that 28 % of eld-
erly patients with HF developed new-onset type 2 DM in
3 years and HF is an independent risk factor for type 2
DM (OR 3.3; 95 % CI 2.6–4.0) [6]. Patients with HF are
not only at increased risk of developing DM but patients
with DM also have a greater probability of developing
HF [7]. In patients with DM, every unit increase in gly-
cosylated hemoglobin (HbA1c) is associated with a 10 %
to 15 % increased risk of developing HF [8]. Recent lit-
erature suggested that co-existence of DM and HF can
lead to increased morbidity and mortality [9]. Hospital-
ized HF patients with DM have an even worse prognosis
with increased rates of cardiovascular (CV) mortality
and post-discharge HF hospitalization [10]. Recently, a
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subgroup analysis of the results indicated that during
standard treatment, side effects were most likely to ap-
pear in hospitalized HF patients with DM compared to
those without DM [11]. Thus, treating coincident HF
and DM is still a challenge.
Mineralocorticoid receptor antagonists (MRAs) are
powerful treatment agents for patients with cardiovascu-
lar disease [12]. Morbidity and mortality benefits from
treatment with MRAs have been demonstrated in HF
patient and MRAs have become part of standard med-
ical therapy for HF [13, 14]. Similar to HF patients with-
out DM, treatment with MRAs is associated with
improved outcomes in patients with DM [15]. However,
associated adverse events including hyperkalaemia,
gynecomastia, menstrual irregularities, and acute kidney
injury can not be ignored [16]. The effects of MRAs on
glycaemic control are still uncertain. The results of some
studies have demonstrated that spironolactone signifi-
cantly elevated HbA1c levels or worsened glycaemic
control [17, 18], while one study has shown that spir-
onolactone may have a beneficial effect on serum insulin
and HOMA-IR in patients with non-alcoholic fatty liver
disease [19]. A few studies support the view that MRAs,
whether spironolactone or eplerenone, did not have a
significant effect on glucose levels [20–22]. Furthermore,
results of a small direct comparative trial have shown
that spironolactone increased HbA1c in patients with
DM and HF, but eplerenone did not [23].
Aldosterone is a mineralocorticoid hormone that acti-
vates the apical epithelial sodium channel and the baso-
lateral Na+ /K+ ATPase pump, and controls sodium
excretion at the level of the distal tubules to exert an ac-
tion on sodium homeostasis [24]. However aldosterone
can have harmful effects on the cardiovascular system
[25]. By blocking the mineralocorticoid receptor in the
distal tubule of the kidney, MRAs prevent the activation
of sodium channels and lead to diuresis with reduced
excretion of potassium [26]. MRAs can prevent vascular
inflammation, myocardial fibrosis and ventricular re-
modelling, and improve endothelial function [14]. HF
and DM are characterized by a high level of oxidative
stress and it has been reported that MRAs can reduce
oxidative stress [18].
A better understanding of the efficacy and safety of
MRAs in patients with HF and DM is needed. To date,
no meta-analysis has been conducted concerning the re-
lationship between treatment with MRAs and outcomes
in those patients. Therefore, it is worth undertaking a
systematic review to assess the efficacy and safety of
treatment with MRAs in patients with concomitant HF
and DM.
Methods
This systematic review was conducted according to the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (Additional file 1) guidelines [27].
Fig. 1 Flow diagram of study selection. Identified were 2051 potentially relevant articles; 1802 were excluded through screening of titles and
abstracts, and 165 articles were excluded for not meeting our inclusion criteria. Finally, 4 studies were included
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A study was included if it was either a randomised or
non-randomised controlled trial, a prospective or retro-
spective cohort study, or a case–control study that eval-
uated the efficacy and safety of MRAs in patients with
HF and DM.
Types of participants
Patients of any age, gender or race with HF and DM
were included.
Types of interventions
Patients in the treatment groups were given MRAs while
the control groups were given placebo or had no inter-
vention. The studies were included regardless of the
follow-up duration and dosage of treatment.
Types of outcome measures
The primary outcome measures were all-cause mortality
and hyperkalaemia. The secondary outcome measures
were CV mortality or HF hospitalization, death from CV
causes and change in estimated glomerular filtration rate
(eGFR).
Literature search
A computerized literature search was conducted using
Medline (1966–2015), Embase (1980–2015) and the
Cochrane Central Register of Controlled Trials (1991–
2015) from their inception to July 2015. The search
strategy in Medline is shown in Additional file 2. In
addition, we manually searched reference lists of all in-
cluded studies and relevant review articles. Furthermore,
we contacted experts and authors of included studies to
retrieve potentially relevant published or unreported ma-
terial. The retrieval was not restricted by language or
quality of study.
Study selection and data collection
Two reviewers (G.S.P. and Y.H.M.) independently
screened the titles and abstracts to select potential refer-
ences according to a data extraction form established
above, including patients, methods, interventions and
outcomes. For eligible studies, two reviewers (G.S.P. and
Y.H.M.) extracted the data independently. Disagree-
ments were settled through discussion or consultation
with a third author (F.M.D.).
Quality assessment
The quality of the included studies was evaluated using
the nine-star Newcastle Ottawa scale (NOS) [28] by two
investigators. Each study was evaluated based on eight
items, and the scale ranged from zero to nine stars, the
more stars the higher the methodological quality.
Data synthesis and analysis
Data were analyzed using Review Manager (version 5.2).
A fixed-effects model or random-effects model was used
across the studies; relative risk (RR) and 95 % confidence
intervals were calculated for dichotomous outcomes. A
standard chi-square test and I2 statistic were calculated
to evaluate the heterogeneity between trial results. All P
values were two sided and P values of less than 0.05 for
any test were considered to be statistically significant.
Results
Study selection
There were 2051 potentially relevant articles retrieved of
which 1802 were excluded because they were case re-
ports, animal or basic research studies, or did not inves-
tigate any of outcomes of interest. After screening the
titles and abstracts, we excluded 165 articles of the
remaining 169 articles, for not meeting our inclusion cri-
teria. No more eligible studies were found after manually
searching reference lists. Ultimately a total of 4 studies
that included 4742 participants were included in this
systematic review. The screening process is summarized
in a flow diagram (Fig. 1).
Study characteristics
No randomized controlled trials were identified. Three
[29–31] were post hoc subgroup analyses from random-
ized trials and one [32] was a prospective cohort study.
A total of 4742 participants were included in the 4 stud-
ies, of whom 2188 were in treatment groups and 2554
were in control groups. In two studies [29, 30], the
Table 2 Newcastle-Ottawa Scale (NOS) assessment of the quality of the studies
Selection Comparability Outcome Score
Study 1 2 3 4 5a 5b 6 7 8
O’Keefe, et al (2008) [29] ★ ★ ★ ★ ★ ★ ★ ☆ ★ 9
Eschalier, et al (2013) [30] ★ ★ ★ ★ ☆ ☆ ★ ☆ ★ 6
Vaduganathan, et al (2014) [31] ★ ★ ★ ★ ★ ★ ★ ☆ ★ 9
Khosraviani, et al (2014) [32] ★ ★ ★ ★ ☆ ☆ ★ ☆ ☆ 5
Notes: 1 indicates exposed cohort truly representative, 2 the non exposed cohort drawn from the same community, 3 ascertainment of exposure by secure record
or structured interview, 4 outcome of interest was not present at start of study, 5A cohorts comparable on basis of sex and age, 5B cohorts comparable on other
factor(s), 6 quality of outcome assessment, 7 follow-up long enough for outcomes to occur, and 8 complete follow up, ★ yes, ☆ no
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control medicine was placebo (n = 1134); and the
remaining two studies [31, 32] comparison groups with-
out MRAs (n = 1420) were used.
Three studies [29–31] contained additional HF-specific
information (e.g., New York Heart Association Functional
Class or LVEF). These also included demographics,
co-morbidities, other related drug therapies and add-
itional laboratory determination data. One study [32]
was an administrative analysis with no additional labora-
tory or clinical information. Detailed characteristics of
included studies are listed in Table 1.
Risk of bias in included studies
The methodological quality of the included studies is
summarized in Table 2. The NOS results showed an
average overall score of 7.25 (range 5–9).
Effectiveness
All-cause mortality
Three of included studies [29, 31, 32] evaluated the ef-
fect of MRAs on all-cause mortality; 2-year, 16-month
and 9.9-month mortality were evaluated respectively in
these studies. Overall, the mortality was 19 % in the MRA
treatment groups compared with 23 % in control groups
(RR = 0.78, 95 % CI: 0.69–0.88, I 2 = 0 %, P < 0.001; Fig. 2).
All studies suggested MRA-based regimens reduce the
risk of all-cause mortality in comparison to regimens
without MRAs.
In a study by O’Keefe et al. [29], which was a post
hoc analysis from the EPHESUS trial, a reduction in
all-cause mortality was observed in the eplerenone
group that did not reach statistical significance.
Khosraviani et al. [32] observed that spironolactone
significantly reduced mortality compared to the con-
trol group without spironolactone (14.8 vs. 20.0 %, RR
0.74 [95 % CI 0.58–0.93]). Vaduganathan et al. [31] ob-
served that MRA administration was associated with a
31 % reduction in all-cause mortality (RR 0.71 [95 % CI
0.56–0.90]) in unadjusted analyses, but the result
turned to be negative after adjusting for baseline risk
factors (adjusted HR 0.93; 95 % CI 0.75 to 1.15).
CV mortality or HF hospitalization
Two studies [30, 31] evaluated the effects of MRAs on
CV mortality or HF hospitalization. Events occurred in
281 of the 903 participants treated with MRAs (31.1 %)
compared with 288 of 706 (40.8 %) in the control group.
Because significant heterogeneities were detected, we
used a random-effect model to synthesize the data
(RR = 0.73; 95 % CI: 0.52–1.01; I 2 = 83 %; P < 0.06;
Fig. 3). However, these results did not reach statistical
significance.
Eschalier et al. [30] observed that the HR as the pri-
mary outcome in the eplerenone group compared with
the placebo group was 0.61 (95 % CI: 0.49 to 0.76).
Vaduganathan et al. [31] observed that MRA treatment
was associated with a 19 % reduction in the end point
(RR 0.85; 95 % CI 0.73 to 1.00) in unadjusted analyses,
but the results became negative after adjusting for base-
line risk factors (adjusted HR 0.94; 95 % CI 0.80 to 1.10).
Death from CV causes
Two studies [29, 31] evaluated the effect of MRAs on
death from cardiovascular causes. Treatment was
Fig. 2 Forest plot of the comparison of treatment with MRAs versus without MRAs on all-cause mortality. Three of included studies evaluated the
effect of MRAs on all-cause mortality. The mortality was 19 % in MRA groups compared with 23 % in control groups. The studies suggested that
MRAs-based regimens reduced the risk of all-cause mortality in comparison to regimens without MRAs
Fig. 3 Forest plot of comparison of treatment with MRAs versus without MRAs on cardiovascular mortality or heart failure hospitalization. Two
studies evaluated the effect of MRAs on CV mortality or HF hospitalization. Events occurred in 281 of the 903 participants treated with MRAs
(31.1 %) compared with 288 of 706 (40.8 %) in the control group. Because significant heterogeneities were detected, we used a random-effect
model to synthesize the data on the basis of the large population. These results did not reach statistical significance
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associated with a statistically significant reduction in CV
mortality compared with control group (17.5 % versus
20.9 %; RR = 0.83; 95 % CI: 0.70–0.99; I2 = 0 %; P = 0.04;
Fig. 4). Individually, no study observed statistically sig-
nificant reductions in CV mortality.
Safety
Hyperkalaemia
Two studies [29, 30] evaluated the risk of developing
hyperkalaemia caused by MRAs in patients with HF and
DM. The occurrence of hyperkalaemia in the MRA
group was higher than in the comparison group (8.7 %
versus 4.9 %; RR = 1.74; 95 % CI: 1.27–2.38; I2 = 0 %;
P = 0.0005; Fig. 5).
Eschalier et al. [30] observed there was an increase in
the incidence of potassium levels of >5.5 mmol/l with
eplerenone (14.1 %) in patients with DM and HF com-
pared with placebo (8.5 %), P = 0.01. O’Keefe et al. [29]
also observed that hyperkalaemia occurred more fre-
quently with eplerenone treatment than with placebo
(5.6 vs. 3.0 %, P = 0.015).
Change in eGFR
The change in eGFR from baseline to after the treatment
period was reported in one study [30]. No significant dif-
ference was observed in the two groups (P > 0.05).
Discussion
Four studies with 4742 individuals were identified. The
main findings of the present study were that MRA treat-
ment was associated with improved clinical outcomes
compared with those regimens without MRAs in patients
with DM and HF. From a safety perspective, the most ser-
ious adverse effect of MRAs (spironolactone and eplere-
none) is the development of hyperkalaemia. However, as
adverse effects were mentioned in only 50 % of the stud-
ies, there was not sufficient evidence to draw conclusions
on the issue of safety.
There are a number of limitations in this study. First,
only four studies were available; the included studies
were all observational and none of them were random-
ized controlled trials. There were three post-hoc sub-
analyses of randomized controlled trials concerning
MRAs in heart failure and just one prospective cohort
study. Two students scored the quality of each of the ar-
ticles, and quality scores for each study are shown in
Table 2. However, the quality of individual research in-
cluded in our analysis was not necessarily high. Eschalier
et al. [30] did not provide the detailed information about
characteristics of the subject investigated. Khosraviani et
al. [32] failed to offer an elaborated description of the
study design. Thus, the level of evidence for this meta-
analysis does not seem to be high.
Secondly, any systematic review may suffer from publi-
cation or selection bias. Publication bias can be assessed
graphically with a funnel plot, which could not be assessed
owing to having just four available studies. Thirdly, meth-
odology defects have been found in some of these studies,
including failure to collect data prospectively and inad-
equate baseline comparisons. Some baseline characteris-
tics were different among the studies. For example, studies
used different MRAs (spironolactone, eplerenone), differ-
ent controls (placebo control or blank control), different
dosages of the active and control medicines, and different
Fig. 4 Forest plot of comparison of treatment with MRAs versus without MRAs on death from cardiovascular causes. Two studies evaluated the
effect of MRAs on death from cardiovascular causes. Treatment with MRA-based regimens was associated with a statistically significant reduction
in CV mortality compared with other treatments. Individually, in no study were observed statistically significant reductions in CV-cause mortality
Fig. 5 Forest plot of comparison of treatment with MRAs versus without MRAs on hyperkalaemia. Two studies evaluated the risk of developing
hyperkalaemia caused by MRAs in patients with DM and HF. The occurrence of hyperkalaemia in the MRA group was higher than in the
comparison group
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follow-up times and background therapies. Lastly, signifi-
cant heterogeneities were detected when the effects of
MRAs on CV mortality or HF hospitalization were evalu-
ated. The heterogeneity among the studies might be af-
fected by various factors, such as study designs, study
quality and patient characteristics. Therefore, a random-
effect model was used to synthesize the data. But because
only two studies reported these events, we could not per-
form meta-regression meta-analysis to examine the source
of the heterogeneity.
Due to the limited quantity and quality of the included
studies, it is premature to draw conclusion about the ef-
ficacy of MRAs in patients with HF and DM. However,
it should be noted that the absence of sufficient scien-
tific evidence does not mean that the treatment is inef-
fective. The safety of MRA therapy for those patients
remains to be further determined. The possible electro-
lyte trouble could have a multifactorial origin. We ob-
served that when using MRAs, many patients also used
others drugs, including ACE inhibitors, angiotensin re-
ceptor blockers (ARBs), beta-blockers, and aspirin, but
medical therapy was not different at baseline between
the two groups. When the treatment with MRAs was
undertaken, ACE inhibitors or ARBs were generally not
discontinued, but patients underwent a modulation of
their dosages or their dose was left unchanged. This sug-
gests that ACE inhibitors or ARBs could be associated
with the increased risk of hyperkalaemia; MRAs alone
might not have caused this adverse effect. At the stage
of the addition of MRA to therapy, a gradual up-
titration of the MRA dose or a concomitant thoughtful
reduction of the dose of ACE inhibitor or ARB could
prevent the occurrence of hyperkalaemia, except in cases
of severe impairment of kidney function. In addition,
DM is an independent risk factor for the development of
hyperkalaemia [33].
Several implications for research arise from this re-
view. First, more randomized controlled trials of higher
quality, with larger sample size and adequate follow up
are needed to further evaluate the effect of MRAs. Sec-
ond, the only extensively researched MRAs to date are
spironolactone and eplerenone, further research on
other MRAs such as canrenone is encouraged in these
disease areas. Third, we should closely observe the inci-
dence of adverse events, such as electrolyte abnor-
malities, gynecomastia, menstrual irregularities, acute
kidney injury and the effects on serum glucose levels.
Fourth, further study can focus on developing novel
MRAs that have similar outcomes as spironolactone but
lower rates of hyperkalaemia such as finerenone [34, 35].
Fifth, further study is needed with a focus on evaluating
the outcomes of efficacy and safety in patients with heart
failure associated with chronic renal failure, especially in
patients with diabetic nephropathy, which are better
represented in the literature regarding MRA efficacy and
safety.
Conclusions
The available evidence suggests that MRAs can reduce
mortality risk in patients with HF and DM. However, the
development of hyperkalaemia was reported in some of
the reviewed studies. There is still a lack of convincing
evidence for further evaluation of this treatment. More
randomized controlled trials of higher quality, with a lar-
ger sample size, and long-term follow-up are needed in
the future.
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